3月31日,和铂医药公布2024年度业绩,报告显示,截至2024年12月31日,和铂医药全年总收入约2.74亿元人民币(3810万美元),盈利约1941万元人民币(270万美元)。公司已连续两年实现盈利。业内认为,能持续盈利这是该创新药公司商业模式具有可持续性的表现。 业绩较2023年有所下降 虽然业绩正增长,不过,与2023年相比,和铂医药的业绩其实有所下滑。公司在报告期内录得营业收入3810...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.